3-iodobenzylguanidine has been researched along with Alzheimer Disease in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (45.45) | 29.6817 |
| 2010's | 14 (42.42) | 24.3611 |
| 2020's | 4 (12.12) | 2.80 |
| Authors | Studies |
|---|---|
| Blanc, F; Bousiges, O | 1 |
| Durcan, R; Howe, K; Kane, JPM; Lawley, S; Lloyd, JJ; O'Brien, JT; Petrides, GS; Roberts, G; Thomas, AJ | 1 |
| Komatsu, J; Nakajima, K; Okuda, K | 1 |
| Ali, T; Allan, L; Barker, S; Barnett, N; Ciafone, J; Colloby, SJ; Donaghy, PC; Durcan, R; Firbank, MJ; Hamilton, CA; Howe, K; Lawley, S; Lloyd, J; O'Brien, J; Petrides, GS; Roberts, G; Taylor, JP; Thomas, AJ | 1 |
| Boccardi, M; Herholz, K; Nobili, F; Picco, A; Ratib, O; Sonni, I; Varrone, A | 1 |
| Abbasi, M; Afarideh, M; Aghamollaii, V; Ahmadi, M; Farzanefar, S; Ganji, M; Ghalandari, N; Loloee, S; Naseri, M; Tafakhori, A | 1 |
| Arai, H; Arai, T; Asada, T; Fujishiro, H; Hanyu, H; Iizuka, O; Iseki, E; Kashihara, K; Komatsu, J; Kosaka, K; Maruno, H; Mizukami, K; Mizuno, Y; Mori, E; Nakajima, K; Nakamura, H; Nakano, S; Nakashima, K; Nishio, Y; Orimo, S; Samuraki, M; Takahashi, A; Taki, J; Tokuda, T; Urakami, K; Utsumi, K; Wada, K; Washimi, Y; Yamada, M; Yamasaki, J; Yamashina, S; Yoshita, M | 1 |
| Inui, Y; Iwata, N; Manabe, Y; Sarai, M; Toyama, H | 1 |
| De Deyn, PP; Engelborghs, S; Goeman, J; Hauth, L; Martin, JJ; Slaets, S; Van Acker, F; Versijpt, J | 1 |
| Arai, H; Arai, T; Asada, T; Fujishiro, H; Hanyu, H; Iizuka, O; Iseki, E; Kashihara, K; Kosaka, K; Maruno, H; Mizukami, K; Mizuno, Y; Mori, E; Nakajima, K; Nakamura, H; Nakano, S; Nakashima, K; Nishio, Y; Orimo, S; Samuraki, M; Takahashi, A; Taki, J; Tokuda, T; Urakami, K; Utsumi, K; Wada, K; Washimi, Y; Yamada, M; Yamasaki, J; Yamashina, S; Yoshita, M | 1 |
| Kim, JS; Lee, KS; Oh, YS; Park, HE; Park, JW; Song, IU; Yang, DW | 1 |
| Fukasawa, R; Hanyu, H; Hatanaka, H; Hirao, K; Hirose, D; Kanetaka, H; Namioka, N; Sakurai, H; Shimizu, S; Umahara, T | 1 |
| Antelmi, L; Biffi, AM; Calcagni, ML; Capitanio, S; Cecchin, D; Corso, A; Gabanelli, SV; Guerra, UP; Merello, M; Micheli, A; Muscio, C; Nobili, F; Piccardo, A; Pinto, P; Riva, R; Sacco, L; Stefanini, S; Tettamanti, M; Tiraboschi, P; Vai, P; Vidale, S; Volterrani, D | 1 |
| Inui, Y; Kosaka, K; Manabe, Y; Toyama, H | 1 |
| Fujii, K; Furukawa, Y; Kobayashi, S; Morii, H; Saito, T; Shirasaka, T; Tateno, M; Utsumi, K; Yasumura, S | 1 |
| Matsuda, H; Mizumura, S; Waragai, M; Yamada, T | 1 |
| Kinuya, S; Matsuo, S; Nakajima, K; Taki, J; Yoshita, M | 1 |
| Aonuma, K; Asada, T; Homma, T; Kinoshita, T; Kosaka, K; Mizukami, K | 1 |
| Endo, T; Hirokawa, K; Ichihara, K; Kitagawa, M; Kobayashi, T; Kurata, M; Takahashi, M; Toru, S; Uchihara, T | 1 |
| Maeda, K; Sakai, K; Yamane, Y | 1 |
| Kinuya, S; Matsuo, S; Nakajima, K; Okuda, K; Taki, J; Yamada, M; Yoshita, M | 1 |
| Kasahata, N; Makita, Y; Nakamura, A; Orimo, S; Uchihara, T | 1 |
| Ikeda, S; Momose, M; Nakamura, A; Oguchi, K; Ohara, S; Oide, T; Tokuda, T | 1 |
| Kitagawa, Y | 1 |
| Estorch, M | 1 |
| Abe, K; Chikamori, T; Hanyu, H; Hirao, K; Iwamoto, T; Kanetaka, H; Koizumi, K; Shimizu, S; Usui, Y; Yamashina, A | 1 |
| Matsumoto, Y; Nakajima, K; Noguchi-Shinohara, M; Taki, J; Yamada, M; Yokoyama, K; Yoshita, M | 1 |
| Hanyu, H; Hirao, K; Iwamoto, T; Kanetaka, H; Sakurai, H; Shimizu, S | 1 |
| Kitayama, M; Nakashima, K; Nakaso, K; Wada-Isoe, K | 1 |
| Imamura, K; Kitamaya, M; Kowa, H; Nakashima, K; Wada-Isoe, K | 1 |
| Azevedo, JC; Barbirato, GB; Boechat, Y; Cabral, H; Correa, PL; Dohmann, HF; Felix, RM; Manhães, AC; Mendes, MH; Mesquita, CT; Schmidt, GJ; Schmidt, SL; Tolentino, JC | 1 |
| Aiba, I; Doyu, M; Hirayama, M; Ieda, T; Katayama, T; Sobue, G; Takeda, A; Watanabe, H | 1 |
| Taki, J; Yamada, M; Yoshita, M | 1 |
3 review(s) available for 3-iodobenzylguanidine and Alzheimer Disease
| Article | Year |
|---|---|
Biomarkers of Dementia with Lewy Bodies: Differential Diagnostic with Alzheimer's Disease.
Topics: 3-Iodobenzylguanidine; Alzheimer Disease; Biomarkers; Diagnosis, Differential; Humans; Lewy Body Disease; Neurodegenerative Diseases; Tomography, Emission-Computed, Single-Photon | 2022 |
Clinical validity of presynaptic dopaminergic imaging with
Topics: 3-Iodobenzylguanidine; Alzheimer Disease; Biomarkers; Cognitive Dysfunction; Diagnosis, Differential; Heart; Humans; Iodine Radioisotopes; Lewy Body Disease; Nortropanes; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Tomography, Emission-Computed, Single-Photon | 2017 |
Iodine-123-MIBG sympathetic imaging in Lewy-body diseases and related movement disorders.
Topics: 3-Iodobenzylguanidine; Alzheimer Disease; Diagnosis, Differential; Humans; Lewy Body Disease; Parkinson Disease; Radionuclide Imaging; Sympathetic Nervous System | 2008 |
1 trial(s) available for 3-iodobenzylguanidine and Alzheimer Disease
| Article | Year |
|---|---|
Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Alzheimer Disease; Confounding Factors, Epidemiologic; Diagnosis, Differential; Female; Humans; Japan; Lewy Body Disease; Male; Middle Aged; Parkinson Disease; Prevalence; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2006 |
29 other study(ies) available for 3-iodobenzylguanidine and Alzheimer Disease
| Article | Year |
|---|---|
Cardiac
Topics: 3-Iodobenzylguanidine; Adult; Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cohort Studies; Female; Humans; Iodine Radioisotopes; Lewy Body Disease; Male; Middle Aged; Radiopharmaceuticals | 2021 |
What does diagnostic threshold mean? Deterministic and probabilistic considerations.
Topics: 3-Iodobenzylguanidine; Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Humans; Iodine Radioisotopes; Lewy Body Disease; Middle Aged; Probability; Radiopharmaceuticals; Sensitivity and Specificity | 2021 |
Accuracy of Cardiac Innervation Scintigraphy for Mild Cognitive Impairment With Lewy Bodies.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Dysfunction; Diagnosis, Differential; Female; Follow-Up Studies; Heart; Humans; Lewy Body Disease; Male; Myocardial Perfusion Imaging; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon; Tropanes | 2021 |
Potential diagnostic value of
Topics: 3-Iodobenzylguanidine; Adolescent; Alzheimer Disease; Dementia; Diagnosis, Differential; Female; Humans; Lewy Body Disease; Male; Myocardial Perfusion Imaging; ROC Curve | 2017 |
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Alzheimer Disease; Cross-Sectional Studies; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Lewy Body Disease; Male; Myocardial Perfusion Imaging; Sensitivity and Specificity | 2018 |
Comparison of (123)I-MIBG myocardial scintigraphy, brain perfusion SPECT, and voxel-based MRI morphometry for distinguishing between dementia with Lewy bodies and Alzheimer's disease.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Alzheimer Disease; Area Under Curve; Brain; Cohort Studies; Female; Humans; Iodine Radioisotopes; Lewy Bodies; Magnetic Resonance Imaging; Male; Models, Statistical; Models, Theoretical; Perfusion; Reproducibility of Results; Tomography, Emission-Computed, Single-Photon | 2014 |
Diagnostic value of MIBG cardiac scintigraphy for differential dementia diagnosis.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Diagnosis, Differential; Female; Humans; Lewy Body Disease; Male; Middle Aged; Myocardial Perfusion Imaging; Radiopharmaceuticals; Sensitivity and Specificity | 2015 |
Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Alzheimer Disease; Diagnosis, Differential; Female; Humans; Iodine Radioisotopes; Lewy Bodies; Lewy Body Disease; Male; Middle Aged; Myocardial Perfusion Imaging; Reproducibility of Results; ROC Curve; Sensitivity and Specificity | 2015 |
(123)I-MIBG myocardial scintigraphy and neurocirculatory abnormalities in patients with dementia with Lewy bodies and Alzheimer's disease.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Dysfunction; Female; Humans; Hypotension, Orthostatic; Iodine Radioisotopes; Lewy Body Disease; Male; Middle Aged; Neuropsychological Tests; Radionuclide Imaging; Radiopharmaceuticals | 2015 |
Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease.
Topics: 3-Iodobenzylguanidine; Aged, 80 and over; Alzheimer Disease; Diagnosis, Differential; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Lewy Body Disease; Male; Multimodal Imaging; Myocardial Perfusion Imaging; Tomography, Emission-Computed, Single-Photon | 2016 |
(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography and (123) I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: A comparative
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Alzheimer Disease; Corpus Striatum; Diagnosis, Differential; Female; Frontotemporal Dementia; Humans; Lewy Body Disease; Male; Middle Aged; Myocardial Perfusion Imaging; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon; Tropanes | 2016 |
123I-metaiodobenzylguanidine myocardial scintigraphy with early images alone is useful for the differential diagnosis of dementia with Lewy bodies.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Alzheimer Disease; Diagnosis, Differential; Female; Heart; Humans; Lewy Body Disease; Male; Middle Aged; Myocardial Perfusion Imaging; Radiopharmaceuticals; Sensitivity and Specificity | 2017 |
Comparison of the usefulness of brain perfusion SPECT and MIBG myocardial scintigraphy for the diagnosis of dementia with Lewy bodies.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cerebrovascular Circulation; Cysteine; Diagnosis, Differential; Female; Heart; Humans; Lewy Body Disease; Male; Occipital Lobe; Organotechnetium Compounds; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2008 |
Differentiation of early-stage Alzheimer's disease from other types of dementia using brain perfusion single photon emission computed tomography with easy Z-score imaging system analysis.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cysteine; Dementia; Dementia, Vascular; Diagnosis, Differential; Disease Progression; Female; Humans; Image Processing, Computer-Assisted; Lewy Body Disease; Male; Middle Aged; Neuropsychological Tests; Organotechnetium Compounds; Predictive Value of Tests; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2008 |
Decreased ventilatory response to hypercapnia in dementia with Lewy bodies.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Alzheimer Disease; Female; Heart; Heart Rate; Humans; Hypercapnia; Hypotension, Orthostatic; Lewy Body Disease; Male; Myocardial Perfusion Imaging; Neuropsychological Tests; Partial Pressure; Tidal Volume; Ventilation | 2009 |
Depletion or preservation of cardiac sympathetic nerve - an autopsy-verified contrast in two cases of Alzheimer's disease with or without Lewy bodies.
Topics: 3-Iodobenzylguanidine; Adrenergic Fibers; Aged; Aged, 80 and over; Alzheimer Disease; Autopsy; Female; Hippocampus; Humans; Lewy Bodies; Lewy Body Disease; Male; Myocardium; Neurofilament Proteins; Radiopharmaceuticals; tau Proteins; Tyrosine 3-Monooxygenase | 2010 |
Dementia with Lewy bodies is associated with higher scores on the Geriatric Depression Scale than is Alzheimer's disease.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Comorbidity; Depressive Disorder; Diagnosis, Differential; Female; Humans; Lewy Body Disease; Male; Mental Status Schedule; Personality Inventory; Psychometrics; Radiopharmaceuticals; Retrospective Studies; Statistics as Topic; Tomography, Emission-Computed, Single-Photon | 2011 |
Standardization of metaiodobenzylguanidine heart to mediastinum ratio using a calibration phantom: effects of correction on normal databases and a multicentre study.
Topics: 3-Iodobenzylguanidine; Aged; Alzheimer Disease; Calibration; Databases, Factual; Diagnosis, Differential; Humans; Lewy Body Disease; Mediastinum; Myocardium; Phantoms, Imaging; Reference Standards; Retrospective Studies; Societies, Scientific; Tomography, Emission-Computed, Single-Photon | 2012 |
Limbic and nigral Lewy bodies and Alzheimer's disease pathology mimicking progressive supranuclear palsy in a 75-year-old man with preserved cardiac uptake of MIBG.
Topics: 3-Iodobenzylguanidine; Aged; Alzheimer Disease; Diagnosis, Differential; Humans; Lewy Bodies; Limbic System; Magnetic Resonance Imaging; Male; Myocardium; Substantia Nigra; Supranuclear Palsy, Progressive | 2012 |
Usefulness of [123I]metaiodobenzylguanidine ([123I]MIBG) myocardial scintigraphy in differentiating between Alzheimer's disease and dementia with Lewy bodies.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Female; Heart; Humans; Lewy Bodies; Male; Middle Aged; Radiopharmaceuticals; tau Proteins; Tomography, Emission-Computed, Single-Photon | 2003 |
Usefulness of [123I] MIBG myocardial scintigraphy for differential diagnosis of Alzheimer's disease and dementia with lewy bodies.
Topics: 3-Iodobenzylguanidine; Alzheimer Disease; Diagnosis, Differential; Heart; Humans; Lewy Body Disease; Radionuclide Imaging; Radiopharmaceuticals | 2003 |
From the heart to the brain via cardiac MIBG imaging.
Topics: 3-Iodobenzylguanidine; Aged; Alzheimer Disease; Brain; Clinical Trials as Topic; Diagnosis, Differential; Heart; Humans; Lewy Body Disease; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon | 2006 |
Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease.
Topics: 3-Iodobenzylguanidine; Aged; Alzheimer Disease; Brain; Diagnosis, Differential; Humans; Iofetamine; Lewy Body Disease; Perfusion; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon | 2006 |
Phenylephrine and pilocarpine eye drop test for dementia with Lewy bodies and Alzheimer's disease.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Alzheimer Disease; Diagnosis, Differential; Female; Humans; Iodine Radioisotopes; Iris; Lewy Body Disease; Male; Miosis; Miotics; Mydriasis; Mydriatics; Ophthalmic Solutions; Phenylephrine; Pilocarpine; Predictive Value of Tests; Pupil | 2007 |
Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Brain; Diagnosis, Differential; Enzyme-Linked Immunosorbent Assay; Humans; Lewy Body Disease; Middle Aged; Peptide Fragments; Phosphorylation; Predictive Value of Tests; Radionuclide Imaging; Radiopharmaceuticals; ROC Curve; tau Proteins | 2007 |
Serum heart-fatty acid binding protein levels in patients with Lewy body disease.
Topics: 3-Iodobenzylguanidine; Aged; Alzheimer Disease; Area Under Curve; Biomarkers; Diagnosis, Differential; Dopamine Agonists; Fatty Acid Binding Protein 3; Fatty Acid-Binding Proteins; Female; Heart; Humans; Lewy Body Disease; Male; Mediastinum; Parkinson Disease; Radiopharmaceuticals; ROC Curve; Tomography, Emission-Computed, Single-Photon | 2008 |
Value of combining activated brain FDG-PET and cardiac MIBG for the differential diagnosis of dementia: differentiation of dementia with Lewy bodies and Alzheimer disease when the diagnoses based on clinical and neuroimaging criteria are difficult.
Topics: 3-Iodobenzylguanidine; Aged; Alzheimer Disease; Diagnosis, Differential; Fluorodeoxyglucose F18; Heart; Humans; Image Enhancement; Lewy Body Disease; Male; Radionuclide Imaging; Radiopharmaceuticals | 2008 |
Cardiac (123)I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease.
Topics: 3-Iodobenzylguanidine; Aged; Alzheimer Disease; Female; Humans; Lewy Body Disease; Male; Middle Aged; Myocardium; Radionuclide Imaging; Radiopharmaceuticals | 2001 |
A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Alzheimer Disease; Diagnosis, Differential; Female; Heart; Humans; Hypotension, Orthostatic; Lewy Body Disease; Male; Middle Aged; Myocardium; Neuropsychological Tests; Radionuclide Imaging; Radiopharmaceuticals; Sympathetic Nervous System; Time Factors | 2001 |